Although anti-VEGF therapy, for instance with bevacizumab, does have side effects such as hypertension [63] and thereby careful treatment strategy is recommended [64], the success of clinical trials in cancer with double anti-angiogenic approaches has motivated researchers in cerebrovascular diseases to focus on both VEGF and EGFR signaling pathways. This evidence concerns the gene VEGFA and hypertensive disorder.